Home / Resources and Insights / Accelerating Novel Peptides into Clinical Trials with Integr...
Accelerating Novel Peptides into Clinical Trials with Integrated Partnership
Less than 1 min read time
Do you have peptide drug candidates in development?
Do you have peptide drug candidates in development?
Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director, Biopharmaceutical Development and Manufacturing at Neuraly and William Fang, Head of Oligo/Peptide Business at WuXi STA about how an integrated CMC partnership was critical in accelerating a novel peptide to phase 1 clinical trial.
Gated content
Please complete the form below to access this content.
Related Reading
Overcoming Key Challenges in PROTAC Drug Development
Pharmaceutical development of PROTAC (Proteolysis Targeting Chimeras) molecules presents significant challenges due to their complex molecular structures, leading to low...
Oligonucleotide Drug Discovery
